ALVO
HOLD / NEUTRALMeanRevComposite
43.60
Technical
51.00
Fundamental
41.20
Rank
—
Price
3.99
Hurst
0.25
As of
Aug 20, 2026
Daily
Alvotech
HealthcareDrug Manufacturers - Specialty & GenericAlvotech develops and produces biosimilar medications across multiple therapeutic categories including autoimmune disorders, ophthalmology, oncology, and bone health. The company's portfolio includes biosimilars designed to replicate treatments for conditions such as rheumatoid arthritis, psoriasis, Crohn's disease, age-related macular degeneration, cancer-related bone complications, and asthma, among others. Founded in 2013 and headquartered in Luxembourg, the firm operates through subsidiaries serving patients globally.
Market cap
$1.9B
P/E (trailing)
—
P/E (forward)
23.39
PEG ratio
—
Dividend yield
—
Beta
0.22
52w range
2.94 – 9.25
Return on equity
—
Profit margin
-36.31%
Revenue growth
-38.90%
Earnings growth
—
Price history
1Y: 5.10 (-34.8%) · range 3.00–8.98
Cycle position
67/ 100 cycle scoreAPPROACHING EXIT
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 11 · NOT READY · exit proximity 18
Conviction
35/ 100 · maturity 14%
VScore.0911
Buildup.3066
EMA entry setup.3811
Fundamentals.2341
Volume profile
POC
3.38
Price vs POC
+50.9%
Overhead supply
13%
Runway
open sky
Value area 3.10–4.18 · 13% of 120d volume overhead · clean runway
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +23.89% | +26.00% | 15/20d |
| 40d | +23.89% | +26.00% | 15/40d |